Skip to content
OpenCapital
Get started

BridgeBio Pharma BBIO Q3 2025 earnings

Reported October 29, 2025 · After market close

Revenue$120.7MMiss by $27.5MDiluted EPS-$0.95Miss by $0.07
Revenue estimate$148.2M
EPS estimate-$0.88

Next report

Aug 4, 2026 (In 3 weeks)
Revenue estimate$220.2M
EPS estimate-$0.64

Financials

Q3 2025

Income statement

See full
Revenue$120.7M+4,318%
Gross profit$114.1M+5,249%
Operating income-$145.2M+24.3%
Net income-$184.9M-12.6%
EPS (diluted)-$0.95-10.5%

Balance sheet

See full
Cash & equivalents$645.1M+58.2%
Total debt$2.1B+360%
Total equity-$1.9B-57.2%
Total assets$998.3M+50.1%

Cash flow

See full
Operating cash flow-$109.6M+39.3%
CapEx$470.0K+243%
Free cash flow-$110.0M+39.1%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$9.93B+107%
Enterprise value$11.34B+135%
P/S28.1×+6.1×

Profitability

See full
Gross margin95.8%-3.1pp
Operating margin-172.4%-40.8pp
Net margin-227.7%+28.5pp
FCF margin-165.6%—

Returns & leverage

See full
Current ratio3.9×+0.7×

Segments

By product

See full
Cost of license, services, and royalty revenue$9.1M—
License and services revenue$8.3M—

By segment

See full
Reportable Segment$120.7M+4,318%

Versus estimates

Revenue

Q1 2026$194.5MBeat by $16.4MQ4 2025$154.2MBeat by $7.3M
Q3 2025$120.7MMiss by $27.5M
Q2 2025$110.6MBeat by $2.4MQ1 2025$116.6MBeat by $48.2MQ4 2024$5.9MBeat by $1.8M

Diluted EPS

Q1 2026-$0.84Miss by $0.14Q4 2025-$1.00Miss by $0.29
Q3 2025-$0.95Miss by $0.07
Q2 2025-$0.95Miss by $0.12Q1 2025-$0.88Beat by $0.12Q4 2024-$1.31Miss by $0.22

Ask the moment BridgeBio Pharma reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did BridgeBio Pharma report Q3 2025 earnings?
BridgeBio Pharma (BBIO) reported Q3 2025 earnings on October 29, 2025 after market close.
What were BridgeBio Pharma's Q3 2025 revenue and EPS?
BridgeBio Pharma reported revenue of $120.7M and diluted EPS of $-0.95 for Q3 2025.
Did BridgeBio Pharma beat estimates in Q3 2025?
Revenue missed the consensus estimate of $148.2M by $27.5M. EPS missed the consensus estimate of $-0.88 by $0.07.
How did BridgeBio Pharma's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 4318.0% from $2.7M a year earlier and diluted EPS declined 10.5% from $-0.86.
Where can I find BridgeBio Pharma's Q3 2025 SEC filings?
You can read the 10-Q periodic report (0001743881-25-000012) directly on SEC EDGAR. The filing index links above go to sec.gov.